Literature DB >> 12393358

Phenotyping malignant hyperthermia susceptibility by measuring halothane-induced changes in myoplasmic calcium concentration in cultured human skeletal muscle cells.

T Girard1, S Treves, K Censier, C R Mueller, F Zorzato, A Urwyler.   

Abstract

BACKGROUND: Malignant hyperthermia (MH) is a potentially lethal disease triggered by volatile anaesthetics and succinylcholine in genetically predisposed individuals. Because of the heterogenetic nature of MH, a simple genetic-based diagnostic test is not feasible and diagnosis requires an invasive open muscle biopsy followed by the in vitro contracture test (IVCT). Our aim was to establish if measurements of halothane-induced increases in intracellular calcium ion concentration [Ca(2+)](i) in cultured human skeletal muscle cells can be used to phenotype MH susceptibility and if different mutations in the ryanodine receptor (RYR1) gene affect halothane-induced increases in [Ca(2+)](i).
METHODS: Primary cultures of human skeletal muscle cells were established from 54 individuals diagnosed by the IVCT according to the protocol of the European MH Group as: MH susceptible (n=22), MH negative (n=18) or MH equivocal (n=14). All individuals were screened for the presence of the most common mutations in the RYR1 gene. [Ca(2+)](i) was measured by fluorescent digital microscopy using fura-2/AM in 10 cells from each patient at five different halothane concentrations.
RESULTS: The halothane-induced increase in [Ca(2+)](i) differed significantly between the three diagnostic groups. Different mutations of the RYR1 gene did not have a specific impact on halothane-induced increases in [Ca(2+)](i).
CONCLUSIONS: Measurements of [Ca(2+)](i) in human skeletal muscle cells can be used to phenotype MH susceptibility; however, we did not observe a specific effect of any mutation in the RYR1 gene on the halothane-induced increase in [Ca(2+)](i).

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12393358     DOI: 10.1093/bja/aef237

Source DB:  PubMed          Journal:  Br J Anaesth        ISSN: 0007-0912            Impact factor:   9.166


  6 in total

1.  Allele-specific differences in ryanodine receptor 1 mRNA expression levels may contribute to phenotypic variability in malignant hyperthermia.

Authors:  Hilbert Grievink; Kathryn M Stowell
Journal:  Orphanet J Rare Dis       Date:  2010-05-19       Impact factor: 4.123

Review 2.  Preclinical model systems of ryanodine receptor 1-related myopathies and malignant hyperthermia: a comprehensive scoping review of works published 1990-2019.

Authors:  Tokunbor A Lawal; Emily S Wires; Nancy L Terry; James J Dowling; Joshua J Todd
Journal:  Orphanet J Rare Dis       Date:  2020-05-07       Impact factor: 4.123

3.  Effects of Remimazolam and Propofol on Ca2+ Regulation by Ryanodine Receptor 1 with Malignant Hyperthermia Mutation.

Authors:  Tomoyuki Watanabe; Hirotsugu Miyoshi; Yuko Noda; Soshi Narasaki; Atsushi Morio; Yukari Toyota; Hiroshi Kimura; Keiko Mukaida; Toshimichi Yasuda; Yasuo M Tsutsumi
Journal:  Biomed Res Int       Date:  2021-01-04       Impact factor: 3.411

4.  Anomalous Kv 7 channel activity in human malignant hyperthermia syndrome unmasks a key role for H2 S and persulfidation in skeletal muscle.

Authors:  Valentina Vellecco; Alma Martelli; Iris Sofia Bibli; Marianna Vallifuoco; Onorina L Manzo; Elisabetta Panza; Valentina Citi; Vincenzo Calderone; Gianfranco de Dominicis; Caterina Cozzolino; Elisabetta M Basso; Martina Mariniello; Ingrid Fleming; Antonio Mancini; Mariarosaria Bucci; Giuseppe Cirino
Journal:  Br J Pharmacol       Date:  2019-05-03       Impact factor: 8.739

Review 5.  Exercise-induced rhabdomyolysis and stress-induced malignant hyperthermia events, association with malignant hyperthermia susceptibility, and RYR1 gene sequence variations.

Authors:  Antonella Carsana
Journal:  ScientificWorldJournal       Date:  2013-02-10

Review 6.  Central core disease.

Authors:  Heinz Jungbluth
Journal:  Orphanet J Rare Dis       Date:  2007-05-15       Impact factor: 4.123

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.